Thu Apr 4, 2013 9:32am EDT (Reuters) - Merrimack Pharmaceuticals Inc said certainly one of three individual groups in a mid-stage trial of its experimental lung cancer medicine did not meet the main goal of improving survival rates after four months of therapy minus the condition worsening. The business's shares fell 7 per cent in premarket business. The group was used the drug, MM-121, in combination with erlotinib, an approved cancer treatment, for non-small cell lung cancer. Erlotinib is promoted as Tarceva by Swiss drugmaker Roche Holding AG. The key purpose of the study was showing that 40 % of the 50-patient party experienced a survival after four weeks. The substance is also being examined in two different lung-cancer patient groups, and in independent studies for ovarian and breast cancer. Another cancer drug from the company, MM-398, is being tested in a late-stage test for pancreatic cancer. It's also being tried as a treatment for glioma and colorectal cancer. Shares of the business, which went public in March 2012, were down 7 percent at $5.75 in trading prior to the bell. They shut at $6.21 on the Nasdaq on Wednesday. (Reporting by Esha Dey in Bangalore; Editing by Sriraj Kalluvila)
More Info: FAO calls for "strong biosecurity measures" by the new avian influenza virus
No comments:
Post a Comment